摘要
目的 :探讨基质金属蛋白酶MMP 2和MMP 9与宫颈鳞癌的发生、发展及转移的关系。方法 :免疫组化S P法测定MMP 2和MMP 9表达及分布 ;明胶酶谱法测定活性型MMP 2及MMP 9蛋白的含量 ;RT PCR技术检测MMP 2及MMP 9mRNA表达水平。结果 :宫颈癌组织中MMP 2及MMP 9的阳性表达率为 77 78%和 6 6 6 7% ,明显高于在CIN(1 0 %及 2 0 % )及正常宫颈组织中表达率。淋巴转移组MMP 2及MMP 9的阳性率均显著高于非淋巴转移组 ,P <0 0 5。在宫颈鳞癌组织中MMP 2及MMP 9酶活性显著高于CIN及正常宫颈组织 ,P <0 0 1。MMP 2及MMP 9mRNA在宫颈鳞癌中的表达量亦显著高于在CIN及正常宫颈组织的表达量 ,P <0 0 1。结论 :MMP 2及MMP 9与宫颈鳞癌的发生、发展及转移有关 ,MMP 2及MMP
Objective To investigate the relationship between the expression of matrix metalloproteinases (MMP 2,MMP 9) and tumorigenesis,development and metastasis of cervical squamous cell carcinoma.Methods The expression and distribution of MMP 2,MMP 9 proteins were detected by using the immunohistochemical S P method.Their active proteins and mRNA were analyzed by the gelatin zymography and RT PCR respectively.Results MMP 2 and MMP 9 proteins majorly localized in the plasma,minor in the membrane.The positive expression rates of MMP 2 and MMP 9 were 77 78 and 66 67% respectively,in the carcinoma tissues.The rate in the subgroup with lymphatic metastasis was significantly higher than that in the group without metastasis, P <0 05.The presence of MMP 2 and MMP 9 proteins showed no relationship between pathologic grade,clinical stage and the size of the carcinoma.In CIN,the positive rates for this two proteins were 10% and 20% respectively.However,they were absent in normal tissues.The activities of MMP 2 and MMP 9 in carcinoma tissues,which analyzed by the gelatin zymography were statistically higher than those in CIN and normal cervices, P <0 01.MMP 2 mRNA and MMP 9 mRNA were significantly higher in carcinoma than those in CIN and normal cervices, P <0 01.Conclusions MMP 2 and MMP 9 correlate well with the occurrence,invasion and metastasis of cervical squamous cell carcinoma.The two indicators can be used to identify the metastasis trend of cervical carcinoma in clinic.
出处
《肿瘤防治杂志》
2003年第7期718-721,共4页
China Journal of Cancer Prevention and Treatment
关键词
宫颈肿瘤
癌
鳞状细胞
金属蛋白酶类
对照临床试验
肿瘤转移
cervix neoplasma
carcinoma,squamons cell
metalloproteinase
controlled clinical trials
neoplasms metastasis